DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kineret (Anakinra) - Summary



Kineret® (anakinra) is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). Kineret® differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus.

Kineret® is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). Kineret® can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents (see WARNINGS).

See all Kineret indications & dosage >>


Media Articles Related to Kineret (Anakinra)

Rheumatoid arthritis linked to increased risk of preterm birth, low birth weight
Source: Arthritis / Rheumatology News From Medical News Today [2014.11.13]
Children of mothers with rheumatoid arthritis are more likely to be delivered preterm and have a lower birth weight than children of mothers without the condition, a study finds.

Rheumatoid Arthritis in Moms-to-Be Linked to Premature Births
Source: MedicineNet Rheumatoid Arthritis Specialty [2014.11.13]
Title: Rheumatoid Arthritis in Moms-to-Be Linked to Premature Births
Category: Health News
Created: 11/13/2014 12:00:00 AM
Last Editorial Review: 11/13/2014 12:00:00 AM

New effective, safe and cheap treatment strategy for rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2014.11.11]
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost.

Lower Doses of Rheumatoid Arthritis Drugs May Work for Some
Source: MedicineNet Rheumatoid Arthritis Specialty [2014.11.06]
Title: Lower Doses of Rheumatoid Arthritis Drugs May Work for Some
Category: Health News
Created: 11/5/2014 12:00:00 AM
Last Editorial Review: 11/6/2014 12:00:00 AM

Researchers identify new cell signaling pathway thought to play role in rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2014.10.25]
A new study by researchers at Hospital for Special Surgery (HSS) identifies a new cell signaling pathway that contributes to the development and progression of inflammatory bone erosion, which...

more news >>

Published Studies Related to Kineret (Anakinra)

Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. [2011.07]
CONTEXT: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors. OBJECTIVE: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1... CONCLUSIONS: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]
OBJECTIVES: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA)... CONCLUSIONS: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number: NCT00339157.

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). [2010.05.15]
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role...

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. [2009.03.15]
OBJECTIVE: To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee... CONCLUSION: Anakinra was well tolerated as a single 50-mg or 150-mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. [2009.02]
This study assessed the safety and preliminary efficacy of the interleukin-1 receptor antagonist anakinra in patients with polyarticular-course juvenile rheumatoid arthritis (JRA). Eighty-six patients entered a 12-week open-label run-in phase (1 mg/kg anakinra daily, < or =100 mg/day)... These results indicate that anakinra 1 mg/kg once daily (< or =100 mg/day) is safe and well tolerated in patients with JRA.

more studies >>

Clinical Trials Related to Kineret (Anakinra)

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria [Completed]
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.

Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU. This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) [Completed]
The purpose of this study is to evaluate the percentage of subjects in Australian clinical practice continuing treatment with Anakinra (Kineret®) at the end of study week 48 in subjects with active RA. The continued use of Kineret® will be based on pre-defined response assessment criteria for subjects with active RA.

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire [Completed]
The primary purpose of this study is to assess the ease-of-use of SimpleJectTM compared to pre-filled syringe(s) when using Kineret® in RA subjects. The secondary purpose of this study is to assess the level of fear and anxiety associated with the use of both injection methods, to assess safety when using SimpleJectTM and to evaluate the Ease-of-Administration Questionnaire (EAQ) in terms of the quality of items, item performance, and the instrument reliability.

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis [Recruiting]

- Severe atopic dermatitis, also known as eczema, is a chronic inflammatory skin

condition that affects both children and adults and causes severe itching and skin redness. Current treatments of atopic dermatitis include topical creams and lotions, light therapy, and medications. However, the difficulty with long-term treatment for the chronic and severe nature of the disease requires more effective and better-tolerated therapeutic options.

- Anakinra is a drug that blocks a substance called interleukin-1 (IL-1), which may be

important in causing the inflammation in atopic dermatitis. Researchers are interested in determining whether anakinra can be used to help treat atopic dermatitis. Anakinra has been approved by the Food and Drug Administration to treat rheumatoid arthritis in adults and children, but it has not been approved for use in adults or children with atopic dermatitis and is considered an experimental treatment in this study. In this study Anakinra will be administered as an injection under the skin every day for 3 months


- To assess the safety and effectiveness of using anakinra to treat severe atopic dermatitis

in children.


- Children between 10 and 18 years of age who have been diagnosed with severe atopic

dermatitis that has not responded to standard treatment.


- Initial Screening: Participants will have an initial screening visit with a complete

physical examination and medical history, blood and urine tests, photographs of the skin ,skin biopsy, and other tests as required.

- Run-in Period: At the screening visit, participants will receive a diary card and will

be asked to track their atopic dermatitis symptoms on standard treatment for 2 months.

- Start of Treatment: At the end of the 2 month Run-in period participants will return

for an inpatient visit (2 days) to receive the initial dose of anakinra and will be watched for any side effects. During the inpatient visit, participants will have additional examinations and blood and urine tests, and will be instructed on how to administer the anakinra injections at home.

Treatment Period: - Participants will return once a week for the first 2 weeks of treatment,

at the end of the first month, and then once a month for the following 2 months, for a physical exam and blood tests. Participants will be asked to record symptoms related to their atopic dermatitis, anakinra administration and any side effects related to the anakinra on the diary card. The diary cards will be reviewed and collected at each visit.-

End of Treatment Period: At the end of 3 months of treatment with anakinra, participants will again be asked to record symptoms related to their atopic dermatitis on the diary card. Participants will be seen once a month for 3 months for a physical exam, blood tests and review of the diary card. . The final study visit will take place at the end of the 3rd month and will include a physical exam, blood tests, photographs and skin biopsy.

Anakinra or Denosumab and Everolimus in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) that can be given to patients with advanced cancer. The safety of these drugs will also be studied.

Everolimus is designed to stop cells from dividing.

Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and spread of cancer.

Denosumab is designed to block the activity of a protein, which may prevent bone complications in cancer that has spread to the bone.

more trials >>

Reports of Suspected Kineret (Anakinra) Side Effects

Pyrexia (8)Alanine Aminotransferase Increased (6)Rash (6)Dyspnoea (4)Vomiting (4)Cytolytic Hepatitis (4)Aspartate Aminotransferase Increased (4)Leukopenia (4)Liver Injury (3)Drug Ineffective (3)more >>

Page last updated: 2014-11-13

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014